Advances in chimeric antigen receptor T (CAR-T) cell therapy and limitations for treating breast cancer requires next generation of CAR-T cells treatment
Year: 2026
Type: article
Abstract: Breast cancer is very common syndrome and an important reason of cancer-related death among females around world. Although targeted treatments and chemotherapy have enhanced outcomes in specific subtypes, such as TNBC with less treatment possibilities and poor prognosis. Immunotherapy with (CAR)-T cells therapy showing useful progress in blood diseases; however, its application in breast cancer remains challenging. This study aimed to summarize the current progress, therapeutic potential and future directions of next-generation CAR-T cells treatment for BC. A comprehensive review of recent preclinical studies, clinical trials, and evolving approaches related to CAR-T cell treatment in BC was conducted. Google scholar, PubMed, Scopus, Web of Science, and Google was employed to retrieve the studies. CAR-T cell targeting breast cancer associated antigens such as MUC1, HER2, TROP2, GD2, ROR1, and EpCAM exhibit helpful antitumor activity. Mesothelin molecule expressed on different hard tumor cells surface is appropriate point for tumor cells with high MSLN expressions for CAR-T-cells treatment. Barriers limit clinical success, with tumor antigen heterogeneity, lack of tumor-specific targets, poor T-cell trafficking, functional exhaustion, and immunosuppressive TME. Safety concerns as tumor toxicity, high cost and difficulty to handle remain significant challenges. Emerging next-generation strategies with armored CAR-T cells, multi-target, logic-gated designs, cytokine-secreting constructs, gene editing, and combined treatment developed to overcome these limitations. Although CAR-T cells treatment is still in initial stages of clinical translation, ongoing advances in cellular engineering, target identification, and combination strategies hold significant promise for improving efficacy and safety. MSLN CAR-T-cells treatment, and other (iNKT), γδ T, and (MAIT) cells, play significant role in innate and adaptive immunity. Moreover, Allo 15MCAR-NKT cells as next-generation; off-the-shelf immunotherapy shows strong treatment potential for TNBC. Next-generation CAR-T approaches may provide transformative therapeutics with advanced and treatment-resistant breast cancer. In future there is need of next generation CARs to work more efficiently.
Source: Cancer Cell International
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: CAR T-cell therapy, breast cancer, triple-negative breast cancer, tumor-associated antigens, MUC1, HER2, TROP2, GD2, ROR1, EpCAM, mesothelin, tumor antigen heterogeneity, T cell exhaustion, immunosuppressive tumor microenvironment, armored CAR-T cells, genome editing, combination immunotherapy, NKT cells, γδ T cells, mucosal-associated invariant T cells, off-the-shelf immunotherapy, treatment resistance
Open Access status: gold
Estimated APC paid: $3,190
OpenAlex ID: W7235335213
